A Phase 3 Study of DU-176b

A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study of DU-176b in patients with non-valvular atrial fibrillation (NVAF) aged 80 years or older who are ineligible for available oral anticoagulation therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223211

Enrollment

800

Registered

2016-05-23

Start date

2016-08-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-valvular atrial fibrillation

Interventions

investigational material(s) Generic name etc : DU-176b INN of investigational material : edoxaban Therapeutic category code : 333 Anticoagulants Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy

Exclusion criteria

Exclusion criteria: Patients with active bleeding Patients who have poorly controlled hypertension Patients who have liver dysfunction accompanied with disorder of blood coagulation

Design outcomes

Primary

Measure	Time frame
efficacy Efficacy outcome (eg, stroke events)	—

Secondary

Measure	Time frame
safety efficacy Safety outcome (eg, bleeding events)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026